Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:27:27.714Z.
Calculation as of: 2026-10-06T18:27:27.714Z.
Quote observation: 2026-10-06T18:23:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c1ebec02882b5d134f555e456bf3ec52d4d7fba3d3c39a772b469d051cfe6f8
PEG RATIO
N/A
Seres Therapeutics, Inc.
Market Cap
$27.45M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | $27.45M | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.02M | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $25.98M | N/A |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $28.86M | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.05M | N/A |
| InspireMD, Inc. (NSPR)vs › | $25.30M | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $25.24M | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.48M | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.53M | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.66M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
